CORONAVIRUS VACCIN MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-91384 | Pharmaceutical And Healthcare
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Coronavirus Vaccin Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL CORONAVIRUS VACCIN MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL CORONAVIRUS VACCIN MARKET
7.1 GLOBAL CORONAVIRUS VACCIN MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA CORONAVIRUS VACCIN MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Inovio Pharmaceuticals, Inc.
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Moderna, Inc.
16.3 Novavax, Inc.
16.4 Protein Potential, LLC
16.5 AlphaVax, Inc.
16.6 Synairgen PLC
16.7 NanoViricides, Inc.
16.8 GGeneCure, LLC
16.9
16.10 Segmentation by Region:
16.11
16.12 North America
16.13 Europe
16.14 Asia Pacific
16.15 Latin America
16.16 Middle East & Africa
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Market by Type :Caused by Coronavirus):
HCoV-229E
HCoV-OC43
SARS-CoV
New Haven CoV
HKU1-CoV
MERS-CoV
Segmentation, by Vaccine Type:
Inactivated coronavirus vaccine
Live attenuated coronavirus vaccine
S-Protein based coronavirus vaccine
Market by Application :
Hospitals
Clinics
Research Institutes
Others
Companies
Inovio Pharmaceuticals, Inc.
Moderna, Inc.
Novavax, Inc.
Protein Potential, LLC
AlphaVax, Inc.
Synairgen PLC
NanoViricides, Inc.
GGeneCure, LLC
Segmentation by Region:
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.